Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Parkinson’s Med Nouriast Fails in PIII Study in US, Europe: Kyowa Kirin
Kyowa Hakko Kirin said on December 13 that its Parkinson’s disease treatment istradefylline, which is sold under the Nouriast brand in Japan, failed to meet the primary endpoint in a PIII study conducted in North America and Europe. The placebo-controlled…
To read the full story
Related Article
- Kyowa Kirin Finally Bags US OK for Parkinson’s Disease Istradefylline
August 29, 2019
- Kyowa Kirin Eyes US Resubmission for Nouriast Next Year
October 18, 2017
BUSINESS
- Pfizer Hails Adult Rollout of Prevenar 20 as “Milestone” for Public Health
April 1, 2026
- Kyorin Exercises Option for BIODOL’s Pain Drug Candidate
April 1, 2026
- UCB Japan Files Zilbrysq Autoinjector in Japan
April 1, 2026
- Tanabe Unveils PIII Data for EPP/XLP Therapy, Backing Filing Plans
March 31, 2026
- Meiji Pharma Invests in Centivax to Support Vaccine R&D
March 31, 2026
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…